ONCAlert | 2017 San Antonio Breast Cancer Symposium

Comparing Bosutinib Versus Imatinib in Newly Diagnosed CML

Jorge Cortes, MD
Published Online: 7:24 PM, Mon June 5, 2017

Jorge Cortes, MD, deputy chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses initial results from the BFORE trial, which is exploring bosutinib (Bosulif) versus imatinib (Gleevec) for newly diagnosed chronic myeloid leukemia.

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.